Skip to content

Robin Shane Readnour, Director at AN2 Therapeutics, sold ANTX on Sep 8, 2026

Data as of Oct 16

▼ SELL$31.9K5,294 shares at $6.02Robin Shane Readnour DirectorANTX AN2 Therapeutics, Inc.
Watch ANTX
Traded
Sep 8, 2026
Disclosed
Sep 8, 2026
Filed
The same day

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Robin Shane Readnour, Director at AN2 Therapeutics, sold ANTX on Sep 8, 2026TRADEDDISCLOSED
ANTXSimilar stocks (XLV — its sector index fund), rebased to ANTX's price on the disclosure day
ANTX since disclosure
−43.5%
after the sale
Similar stocks (XLV) since disclosure
+5.7%
XLV — its sector index fund

Change in closing price from Sep 8, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLRobin Shane Readnour DirectorANTX AN2 Therapeutics, Inc.$28.4Kdisclosed Sep 8 · filed the same day
  2. ▼ SELLRobin Shane Readnour DirectorANTX AN2 Therapeutics, Inc.$19.6Kdisclosed Sep 8 · filed 5 days after the trade · late
  3. ▼ SELLRobin Shane Readnour DirectorANTX AN2 Therapeutics, Inc.$17.5Kdisclosed Sep 8 · filed 5 days after the trade · late

See every trade on ANTX →